Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00674479 | INCB018424 in Patients With Advanced Hematologic Malignancies | completed | Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT00476190 | ALL Adult Consortium Trial: Adult ALL Trial | completed | Phase 2 | 112 | Dana-Farber Cancer InstituteOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT02257138 |
| Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia |
| completed |
| Phase 1 / Phase 2 |
| 30 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jun 8, 2025 |
| clinicaltrials |
| NCT02397720 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT02871219 | Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT03831776 | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis(BosuPeg) | completed | Phase 2 | 212 | St. Olavs HospitalOTHER | 4 | Jun 8, 2025 | clinicaltrials |
| NCT00112827 | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | City of Hope Medical CenterOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05008224 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)(KEYNOTE-C11) | completed | Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Jun 6, 2025 | clinicaltrials |
| NCT03792633 | Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL | completed | Phase 2 | 106 | University of PennsylvaniaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03012880 | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03844997 | Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 35 | Sudipto Mukherjee, MD, PhD, MPHOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02937662 | Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML | completed | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT02988466 | Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT | completed | Phase 2 | 78 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT02329847 | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 144 | Janssen Research & Development, LLCINDUSTRY | 6 | May 25, 2025 | clinicaltrials |
| NCT03490344 | Short Course Daratumumab in Patients With Multiple Myeloma | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04062448 | A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) | completed | Phase 2 | 16 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT03113422 | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy(PrE0403) | completed | Phase 2 | 56 | PrECOG, LLC.OTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03361748 | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma(KarMMa) | completed | Phase 2 | 149 | CelgeneINDUSTRY | 8 | May 23, 2025 | clinicaltrials |
| NCT04325841 | Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children | completed | Phase 2 | 2 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT04340167 | Study of Anti-CD22 CAR-T Cells Treating Leukemia Children | completed | Phase 2 | 14 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT04689659 | Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma | completed | Phase 2 | 55 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT01350245 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | completed | Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03149055 | Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) | completed | Phase 2 | 99 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04176380 | RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma | completed | Phase 2 | 15 | Rapa Therapeutics LLCINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT02580539 | A Study of the Safety and Efficacy of EBV Specific T-cell Lines(EBV-TCL-01) | completed | Phase 1 / Phase 2 | 12 | Dr. Jean-Sebastien Delisle, MD, PhDOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03583424 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03618641 | CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | completed | Phase 2 | 34 | Diwakar DavarOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05149378 | Venetoclax Based Regimen for R/R T-ALL | completed | Phase 2 | 25 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT00179673 | Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 43 | CelgeneINDUSTRY | 2 | May 13, 2025 | clinicaltrials |
| NCT04402138 | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | completed | Phase 2 | 15 | SCRI Development Innovations, LLCOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT01729091 | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT00429143 | A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative | completed | Phase 1 / Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03417284 | Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT00135200 | Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma | completed | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT00410423 | Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias | completed | Phase 1 / Phase 2 | 55 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01162096 | Reduced Intensity Haploidentical Transplant for Hematological Malignancies | completed | Phase 1 / Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01341301 | Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | completed | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01458366 | Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide | completed | Phase 1 / Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01982682 | Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor | completed | Phase 2 | 41 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT02224729 | Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03008187 | MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia(Diamond-01) | completed | Phase 1 / Phase 2 | 73 | Menarini GroupINDUSTRY | 4 | Apr 29, 2025 | clinicaltrials |
| NCT03412565 | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | completed | Phase 2 | 265 | Janssen Research & Development, LLCINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT05347485 | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | completed | Phase 2 | 86 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT02566304 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 35 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03860038 | TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 113 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Apr 24, 2025 | clinicaltrials |
| NCT02717507 | Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors | completed | Phase 2 | 196 | Children's Oncology GroupNETWORK | 4 | Apr 23, 2025 | clinicaltrials |
| NCT04487106 | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04795427 | Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | completed | Phase 2 | 84 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02658487 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia(VITAL) | completed | Phase 2 | 42 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 15, 2025source: clinicaltrials